Thermo Fisher Charts Impressive Q4 Results, Divests Pathology Business To PHC
Executive Summary
Thermo Fisher Scientific has surprised analysts with its Q4 and full year 2018 results. The US-based company reported an 8% increase in fourth-quarter revenues, year-over-year, led by steady growth across its four business segments.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q1 2019
Device financing totaled $1.6bn for the first quarter of 2019. Late-stage venture rounds were the most active category, led by Nuvaira's $79m Series E financing. Merger and acquisition activity reached $7.3bn; in the largest transaction of the quarter, Ethicon acquired Auris Health for up to $6bn. Diagnostics/research financing reached $1.7bn, and ten diagnostics/research tools companies were acquired, five of which together were valued at $22.6bn.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.